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PURPOSE. The purpose of this study was to evaluate dendritic cell (DC) distribution,
morphology, and DC density in the entire cornea of medically controlled glaucoma patients
(MCGP), using in vivo confocal microscopy (IVCM).
METHODS. Fifty MCGP were enrolled, 15 patients with dry eye, and 15 healthy subjects served
as controls. Patients were asked to complete the Ocular Surface Disease Index (OSDI)
questionnaire and then underwent tear film break-up time (BUT), corneal staining, and
Schirmer test (ST) I and then IVCM. In vivo confocal microscopy evaluated the limbal and
central DC density, the DCs morphology and distribution. Relationships among DC density,
OSDI score, and corneal staining were analyzed.
RESULTS. Medically controlled glaucoma patients were divided into 2 groups; group 1 (29 eyes)
was tested with one drug; group 2 (21 eyes) was tested with ‡2 drugs. Dendritic cells were
significantly higher at limbus than at central cornea in both groups. Limbal DCs were found in
the 86.7%, 89.7%, 90.4%, and 93.3% of eyes in controls, groups 1 and 2, and DED; central
corneal DCs were found in the 26.6%, 75.9%, 80.9%, and 86.6% of eyes in controls, groups 1
and 2, and DED. Dendritic cell density was higher in glaucoma groups and DED than in
controls (P < 0.001). Group 2 and DED presented DC density significantly higher compared
with group 1 (P < 0.05). In group 1 DC density was higher in patients taking preserved drugs
than in those taking preservative-free drugs (P < 0.05). Dendritic cell density was higher in
DED than in group 2 (P < 0.05). Dendritic cell density significantly correlated with corneal
staining and OSDI (P < 0.001).
CONCLUSIONS. Dendritic cells increase in the entire cornea of MCGP, with a higher density at
limbus. These modifications may take part in the induction of the glaucoma-related ocular
surface disease.
Keywords: antiglaucoma therapy, cornea, dendritic cells, glaucoma, glaucoma-related ocular
surface disease, in vivo confocal microscopy, limbus
The daily instillation of IOP-lowering medications producesseveral alterations of the ocular surface in patients with
glaucoma.1,2 Over the past 2 decades, in vivo confocal
microscopy (IVCM), which permits a noninvasive in vivo
cytologic observation of the ocular surface structures greatly
increased the knowledge of these alterations.3–9
In medically controlled glaucoma patients (MCGP), the
cornea is one of the most altered tissues, with modifications
involving all epithelial layers, subbasal nerve plexus, stroma,
and endothelium.4,5 The most prominent changes include
variations of the epithelial cells densities, stromal keratocyte
activation, depletion of subbasal plexus nerves, and polyme-
gathism and pleomorphism of endothelial cells. Antiglaucoma
therapy also deeply affects the limbus in terms of worsening of
transitional epithelium regularity, inflammation of Vogt’s
palisades, and increase in dendritic cells (DCs).8
Dendritic cells are bone marrow-derived professional
antigen-presenting cells (APCs) that populate the interstitial
tissue of solid organs. Within the cornea, which normally hosts
different populations of resident DCs,10 Langerhans cells (a
subpopulation of DCs) represent the main APCs. These cells
modulate the immune response toward pathogenic stimuli
under different conditions, such as dry eye, infective keratitis,
vernal keratoconjunctivitis, and contact lens wear and after
different medical or surgical treatments.11–16
Corneal DCs exist in immature and mature forms with a
unique morphology, although with a different expression of
their features. They may be located at the superficial,
intermediate, or basal epithelium, at the basal lamina, and at
the subbasal nerve plexus layer. Zhivov et al.15 found that in
normal subjects, the DC density declines from peripheral
toward central cornea. In the presence of inflammatory ocular
surface conditions, DCs increases in both the central and
peripheral regions of the cornea and become activated after up-
regulation of MHC class II expression.11
As observed at the limbus, DCs play a significant role in the
development of glaucoma-related ocular surface disease (OSD),
because DC density correlated with the clinical indices of
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ocular surface inflammation.8 To date, no previous study has
specifically investigated DCs in the entire cornea in MCGP and
whether they have a role in the development of the OSD. We
conducted the present study to evaluate the morphology,
distribution, and density of DCs in the central and peripheral
cornea in differently treated MCGP, by using IVCM.
METHODS
Patient Enrollment
This was an observational study that adhered to the tenets of
the Declaration of Helsinki; the institutional review board
approved the study (Department of Medicine and Ageing
Science, G. d’Annunzio University of Chieti-Pescara, Chieti,
Italy). We consecutively enrolled 72 Caucasian patients (50
eyes) who were referred to the Glaucoma Centre, affected
with medically controlled open angle glaucoma. Fifteen age-
and sex-matched patients (15 eyes) with Sjögren syndrome-
related dry eye disease (DED; defined using International Dry
Eye Workshop criteria)17 who also were referred to our Ocular
Surface Diseases Centre and enrolled. Healthy controls
required 15 age- and sex-matched Caucasian subjects (15 eyes)
referred to the General Clinic for the control of refraction.
Written informed consent was obtained from all patients prior
to enrollment, after explanation of the nature and possible
consequences of the study.
Inclusion criteria for patients with glaucoma were best
corrected visual acuity ‡8/10, mean IOP at the time of
diagnosis ‡22 mm Hg and medically controlled at enrollment
(IOP <18 mm Hg; mean of three measurements taken at 9 AM,
12 noon, and 4 PM), central corneal thickness (obtained by
ultrasound pachimetry; Altair; Optikon 2000, Rome, Italy)
ranging from 530 to 570 lm, visual field test (30-2 test, full-
threshold; Humphrey field analyzer II 750; Carl Zeiss Meditec,
Inc., Dublin, CA, USA) showing at least three contiguous points
on the total deviation probability plot at a level less than 2%,
glaucoma hemifield test ‘‘outside normal limits,’’ and ophthal-
moscopic signs of glaucomatous optic consistent with the
visual field alterations. Topical therapy had to be the same in
both eyes, without any variation during the 12 months
immediately prior to enrollment.
The exclusion criteria were history of systemic or ocular
inflammatory diseases and systemic or topical therapies in the
last 12 months that could have modified the corneal status,
previous ocular surgery, laser therapy, trauma, chemical burn,
end-stage glaucoma, pregnancy, and contact lens wear. Patients
with a history of corneal dystrophies and dry eye prior to
glaucoma diagnosis and who were beginning treatment were
also excluded.
Patients with dry eye disease and healthy controls had to
show a best correct visual acuity of ‡8/10, a mean IOP lower
than 18 mm Hg, a central cornea thickness ranging from 530 to
570 lm, absence of glaucomatous optic neuropathy, and a
visual field examination with normal results. At the moment of
enrollment, patients with DED were treated with lubricants at
least five times a day (using preservative-free sodium hyaluro-
nate or carboxymethylcellulose sodium) and did not receive
topical steroids during the last 2 months.
Exclusion criteria for DED were non-Sjögren syndrome-
related dry eye disease, ocular lymphoma, autoimmune
deficiency syndrome, sarcoidosis, diabetes mellitus, corneal
dystrophy, and non–DED-related ocular surface inflammatory
diseases, systemic or topical therapy potential affecting the
corneal status, glaucoma, topical therapy with steroids or non-
steroidal anti-inflammatory drugs, use of contact lens, and
previous ocular surgery. Exclusion criteria for normal controls
were history of systemic or topical therapy, ocular or systemic
diseases in the previous 12 months, pregnancy, and contact
lens wear. Both of the eyes were evaluated, but one eye per
subject was randomly chosen (using a computer-generated
random number list) for statistical analysis.
Patient Clinical Assessment
Each subject enrolled in the study underwent a careful slit
lamp examination of both the anterior and posterior segments
of the eye. Clinical tests included an OSD Index (OSDI)
questionnaire and tear film function tests.
After all patients completed biomicroscopic examination,
they were asked to complete the OSDI questionnaire and
underwent tear film function tests. According to Dry Eye
WorkShop (DEWS) guidelines, tear film break-up time (BUT),
corneal staining, and Schirmer test I (STI; 30 minutes after BUT
measurements) were consecutively performed, after the OSDI
questionnaire was completed.18 Break-up time was recorded as
the average of three consecutive measurements; STI results
were expressed as the length of the strip that was wet after 5
minutes; corneal staining was evaluated with 1% sodium
fluorescein (using the van Bijsterveld method).19
IVCM of the Cornea
Twenty-four hours after clinical assessment, the central corneal
and limbal epithelia were examined using a digital corneal
confocal laser-scanning microscope (HRT III Rostock cornea
module; Heidelberg Engineering GmbH, Dossenheim, Ger-
many) to visualize DCs.
The confocal laser-scanning device was equipped with a
water immersion objective (633/numerical aperture 0.95 W;
Zeiss, Jena, Germany). The device allows for automatic z-
scanning, determining focus depth within the cornea, and
collecting and storing high-contrast digital images of corneal
and limbal layers with a 400 3 400 lm field of view, for a depth
range of 90 lm beginning from the reference layer. The
theoretical confocal section thickness is approximately 10 lm.
This is the slice thickness (voxel), which is imaged by the
confocal microscope to form a two-dimensional pixel-based
digital image; the lateral and transverse resolution is 4 lm.
In vivo confocal microscopy was performed with the
patient under topical anesthesia with 0.4% oxybuprocaine
eye drops. The appropriate positioning and alignment of the
head was maintained with a dedicated movable-target red
fixation light for the fellow eye. A digital camera mounted on a
side arm provided a lateral view of the eye and objective lens to
monitor the position of the lens on the surface of the eye. A
drop of 0.2% polyacrylic gel served as coupling medium
between the poly (methyl methacrylate) contact cap of the
objective lens and cornea.
The examinations were performed at the central cornea (4
3 4 mm) and, afterwards, at the limbus (12, 3, 6, and 9 o’clock
positions, that is superior, temporal, inferior, and nasal
quadrants); sequential images were derived from automatic
scans and manual frame acquisition in the scheduled sectors.
The ‘‘section mode’’ function of the instrument helped to
search for DCs within the corneal and limbal epithelial layers,
enabling instantaneous imaging of a single area at a desired
depth.
Dendritic cells were examined to determine their morphol-
ogy, distribution, and density at both the central cornea and
limbus. Dendritic cells are normally located within the central
and limbal epithelia, the basal lamina, and the subbasal nerve
plexus layer, at a depth of 40 to 60 lm.
Dendritic cells show a different morphology depending on
their maturity and activation. Mature, activated DCs show a
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slender cell body from which a network of long membrane
processes extend resembling dendrites of nerve cells; imma-
ture DCs show a large body with fewer and shorter processes,
if any. Usually, the peripheral cornea is populated by both of
the phenotypes, whereas the central cornea has just the
immature phenotype.14
Forty images from the central cornea, and 60 from the
limbus were acquired from each eye; at least 60 randomly se-
lected high-quality images without motion blur or compression
lines (20 from the central corneal and 40 from the limbus, 10
for each limbal sector) were analyzed to determine DC density.
Dendritic cell density (cells/mm2) was calculated using the
analysis software in the confocal microscope, by averaging
numbers of cells from five images in each position (randomly
selected among the recorded images), counted manually within
a region of interest of standardized dimensions (2503250 lm).
The confocal examination lasted 5 minutes, and none of the
patients experienced significant complications at the end of
the session. A single operator (VF) performed confocal
examinations and selected the images, which were evaluated
by a second operator (LB). The operators were masked from
the subject’s history and from grouping.
The primary outcomes were the mean DC density of the
central cornea and the mean DC density of the entire limbus.
The secondary outcomes were the OSDI score and corneal
staining.
Statistical Analysis
Sample size calculation indicated that at least 50 patients were
necessary to have an a of 0.05 and a b of 0.80. Analysis was
performed using SPSS advanced statistical version 13.0
software (Chicago, IL, USA). Student’s t and chi-squared tests
were used to evaluate age and sex differences (respectively)
between controls, glaucomatous, and dry eye patients. Mann-
Whitney U test was used to determine differences among
groups of patients. Spearman’s correlation was used to analyze
the relationships between DC density and OSDI score, BUT, ST,




Table 1 shows the demographic and clinical data of enrolled
subjects. According to the number of antiglaucoma medica-
tions they were taking, glaucomatous patients were divided
into two groups: group 1 (29 eyes) received monotherapy, and
group 2 (21 eyes) received multitherapy (two or more drugs).
Table 2 shows the treatment of glaucomatous patients at the
moment of enrollment. Therapy for all group 1 patients was
not modified from treatment onset. More than 80% of patients
with DED presented with a severity level 2, according to
criteria previously reported.17
Ocular Surface Clinical Tests
The OSDI questionnaire score, BUT, and fluorescein corneal
staining were significantly different between glaucomatous
groups and controls (Table 3). In overall group 1, the OSDI
score and corneal staining were significantly higher than those
in group 2, whereas BUT and STI were lower (P < 0.05). In
DED, the OSDI score and corneal staining were significantly
higher than those in healthy controls (P < 0.001) and in group
1 (P < 0.05), with BUT and STI lower. No significant
differences were found between DED and group 2. Figure 1
shows the corneal fluorescein staining in glaucoma groups, dry
eyes, and healthy controls.
IVCM of the Cornea
In vivo confocal microscopy clearly distinguished among DCs
in all examined subjects; reliable images of the central cornea
and limbus were obtained in all cases.
DC Morphology
Dendritic cells appeared as hyperreflective elongated cellular
structures, presenting dendritic processes according to their
maturity, and were found mainly at a depth of 35 to 65 lm.
They populated the central cornea extending from the








Mean 6 SD Time Receiving
Therapy, Months†
Controls 57.26 6 5.64 8/7 15.24 6 2.43 þ1.53 6 0.56 NA
DED 55.32 6 4.56 6/9 16.82 6 2.65 þ1.35 6 0.65 72.6 6 11.3
Group 1 58.68 6 3.45 15/14 15.63 6 2.57 3.32 6 0.52* 70.2 6 9.5
Group 2 58.42 6 4.45 11/10 16.58 6 2.25 4.34 6 1.34* 72.8 6 10.3
dB, decibel; DED, dry eye disease; MD, mean defect; NA, not applicable; SD, standard deviation.
* P < 0.05 versus healthy controls and dry eye.
† Time receiving therapy matched with the time of diagnosis.
TABLE 2. Therapy for Glaucomatous Patients
Group Therapy n
Group 1 Single 29
b-blockers 14
Timolol 0.5% (BAK 0.01) 7
PF-timolol 0.5% 7
PGAs 15
Bimatoprost 0.001% (BAK 0.02) 8
PF-tafluprost 0.015% 7
Group 2 Double or more 21
Latanoprost 0.005%-timolol 0.5% fixed
combination (BAK 0.04)
5
Bimatoprost 0.001% (BAK 0.02) and BAK-
preserved timolol 0.5%, unfixed combination
4
Brimonidine 0.2% and timolol 0.5%, fixed
combination (BAK 0.05)
3
Dorzolamide-timolol 0.5% fixed combination
(BAK 0.0075)
4
Bimatoprost 0.001%, brimonidine and timolol
0.5% fixed combination
3
Bimatoprost 0.001%, brimonidine 0.2% (BAK
0.05), and dorzolamide-timolol 0.5% fixed
combination
2
BAK (benzalkonium chloride), % (mg/ml); PF, preservative-free;
PGAs, prostaglandin analogs.
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intermediate epithelial layers to the subbasal nerve plexus, just
above Bowman’s layer; at the limbus, DCs were observed
mainly at the basal layer and basal membrane. However, in
most patients, DCs were found mainly found within the sub-
basal nerve plexus.
Evident morphologic differences were noted between
controls and patients with glaucoma or DED (Fig. 2). In
healthy subjects, corneal and limbal DCs presented a moderate
reflectivity and a mildly elongated cellular body with, very
rarely, small dendritic processes. In cornea and limbus of
glaucomatous and dry eye patients, DCs showed a more
reflective and elongated cellular body with more dendritic
processes and, sometimes, a tendency to cluster.
Morphologic differences were found at both central cornea
and limbus in subclasses of group 1 and between groups 1 and
2. Group 2 and DED were not particularly different from each
other, except for the presence of slightly more elongated DCs
in DED. In group 1, patients taking preserved medications
presented higher evidence of dendritic processes along with a
greater presence of globular cells. Also punctate hyperreflec-
tive elements, which are considered additional confocal signs
of inflammation,4,6,8 were slightly more evident in eyes
receiving benzalkonium chloride (BAK) preserved formula-
tions. Overall, patients treated with prostaglandin analogs
(PGA) presented with higher evidence of mature DCs and with
elongated cellular body and dendritic processes than patients
treated with b-blockers. Clear morphologic differences were
not found between preservative-free (PF) PGA and PF b-
blocker-treated eyes. Compared to patients taking monother-
apy, groups 2 and DED presented highly reflective and mature
DCs, with a greater number of dendritic processes and
tendency to cluster.
In glaucomatous patients receiving multitherapy and dry
eye, DCs presented a higher linear length than those in patients
in the monotherapy group and healthy subjects (up to 30–35
lm versus up to 20–25 lm, respectively).
DC Distribution
In the limbal epithelium, DCs were observed in 86.7% of
healthy subjects (13 of 15 subjects), 89.7% of eyes in group 1
(26 of 29 subjects), 90.4% of group 2 (19 of 21 subjects), and
93.3% of DED (14 of 15 subjects). Differences among groups
were not statistically significant. In the central corneal
epithelium, DCs were observed in 26.6% of healthy eyes (4
of 15 subjects), in 75.9% (22 of 29 subjects) in group 1, in
80.9% (17 of 21 subjects) in group 2, and 86.6% (13 of 15
subjects) in DED. Differences between healthy controls and
patients with DED and glaucoma (both groups) were
statistically significant (P < 0.001); significant differences were
found between DED and group 1 (P < 0.05) but not between
DED and group 2.
DC Density
Limbal and central DC densities are reported in Tables 4 and 5.
In all patients (glaucoma and dry eye) and in healthy controls,
DC density was significantly higher in the limbal epithelium
with respect to the central cornea epithelium.
Limbal DC Density
Limbal DC density was intended as the mean value of the four
quadrants. Limbal DC density was significantly higher in
groups 1 and 2 and DED than in healthy controls. Patients
taking multitherapy or those affected with dry eye presented
values significantly higher with respect to overall patients in
monotherapy. In DED, DC density was overall significantly
higher than in participants in groups 1 and 2.
In group 1, patients treated with preserved medications
showed DC density significantly higher than those in patients
treated with PF medications. Preserved PGA and preserved b-
blockers did not show significant differences between each
TABLE 3. Ocular Surface Clinical Tests
Group Mean 6 SD OSDIs Mean 6 SD BUT Mean 6 SD STI Mean 6 SD Corneal Staining
Controls 7.9 6 0.7* 16.1 6 1.5* 14.3 6 2.3* 0.6 6 1.1*
DED 56.9 6 6.3‡ 3.4 6 1.9‡ 4.3 6 1.7‡ 2.6 6 1.4‡
Group 1 21.3 6 5.7† 11.2 6 2.5† 11.3 6 2.4† 1.6 6 1.3†
PF drugs 18.7 6 4.9 10.9 6 2.1 10.5 6 1.9 1.4 6 1.2
Preserved drugs 23.7 6 3.2 11.5 6 3.1 12.1 6 2.6 1.9 6 1.4
Group 2 51.4 6 7.1 6.6 6 1.4 7.9 6 1.7 2.4 6 1.9
BUT, break-up time; DED, dry eye disease; OSDI, ocular surface disease index; PF, preservative-free; STI, Schirmer test I.
* P < 0.001 versus DED, overall group 1 and group 2.
† P < 0.05 versus group 2.
‡ P < 0.05 versus group 1.
FIGURE 1. Slit lamp biomicroscopy shows the corneal fluorescein staining in healthy controls (A), group 1 ([B] BAK-preserved b-blocker), and
group 2 ([C] BAK-preserved b-blocker/a-agonist fixed combination plus BAK-preserved PGA) and dry eye syndrome (D). Dry eye and multitreated
glaucoma patients present an evident epithelial fluorescein staining compared to monotherapy and healthy controls.
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other; similarly, no significant differences were found between
PF PGA and PF b-blockers. Conversely, preserved PGA showed
significantly higher DC density values than PF PGA and PF b-
blockers. Preserved b-blockers did not show DC density values
higher than those of PF monotherapies. For all considered
parameters, there were no significant differences among the
explored limbal quadrants.
Central Cornea DC Density
Central cornea DC density was significantly higher in group 2
and in DED than in controls; no overall significant differences
were found between group 1 and healthy controls. Overall,
patients receiving monotherapy presented values significantly
lower with respect to patients receiving multitherapy and dry
eye patients. Dendritic cell density was significantly higher in
DED than overall in groups 1 and 2.
In group 1, patients treated with preserved medications
showed DC density values significantly higher than those in
patients treated with PF medications. Preserved PGA and
preserved b-blockers did not show significant differences
between each other; similarly, no significant differences were
found between PF PGA and PF b-blockers. Conversely,
preserved PGA showed significantly higher DC density values
than overall PF monotherapy, whereas preserved b-blockers
did not show higher DC density than overall PF monotherapy.
Correlations
Both limbal and corneal DC density correlated with corneal
staining and OSDI (rho ¼ 0.88 and 0.79, respectively; P <
0.001).
DISCUSSION
Dendritic cells play a crucial role in the innate and adaptive
arms of the immune system in most solid organs, including
cornea. Healthy corneas normally host a large population of
DCs with a density varying from 19 to 100 cells/mm2 in the
central cornea and limbus, respectively.8,11,12,20,21 An inflamed
ocular surface profoundly triggers these cells, which increase
density and change their morphology into the mature
phenotype. Thus, DCs have been considered one of the
hallmarks of corneal inflammation in many diseases.11,22
In MCGP, IOP-lowering medications induce a highly
inflamed ocular surface microenvironment with stimulation
of conjunctival, limbal, and central cornea DCs.1–8 Nonethe-
less, to date, the role of corneal DCs in the development of
FIGURE 2. Dendritic cells at the central cornea and limbus in glaucoma groups, controls, and dry eye patients. Dendritic cells are significantly more
represented in dry eyes (O, P) and group 2 (M, N) than in healthy controls (A, B) and group 1 subclasses (C–L). Group 2 and dry eye patients
present clusters of DCs (asterisks) and some highly reflective globular cells (arrows). In group 1, DCs are slightly more represented in patients
taking preserved medications (E, F; I, L) than respective PF formulations (C, D; G, H). Overall, patients treated with PGA present more
inflammatory signs than patients receiving b-blockers. In preserved PGA, group 2, and dry eye patients, DCs also present evident dendritic
processes (arrowheads). Scale bar: 100 lm.
TABLE 4. DC Density in Controls, Dry Eye, and Glaucoma Groups
Group
Mean 6 SD Central
Cornea DCD, cells/mm2
Mean 6 SD Limbal
DCD, cells/mm2
Controls 7.33 6 4.96* 33.54 6 9.84*
DED 147.00 6 13.29† 200.75 6 17.89†
Group 1 33.96 6 18.77‡ 75.74 6 21.87‡
Preserved drugs 50.84 6 12.23§ 92.07 6 17.75§
PF drugs 20.25 6 9.51 62.46 6 15.07
Group 2 85.34 6 30.21 132.02 6 27.81
DC, dendritic cells; DCD, dendritic cell density; DCL, dendritic cell
length; DED , dry eye disease; PF, preservative-free.
* P < 0.001 versus DED, group 1 and 2.
† P < 0.05 versus group 1 and 2.
‡ P < 0.05 versus group 2.
§ P < 0.05 versus PF drugs.
TABLE 5. DC Density in Group 1
Group
Mean 6 SD Corneal
DCD, cells/mm2
Mean 6 SD Limbal
DCD, cells/mm2
Controls 7.33 6 4.96* 33.54 6 9.84*
DED 147.00 6 13.29 200.75 6 17.89
Preserved b-blockers 42.57 6 9.37† 78.82 6 7.03‡
PF b-blockers 17.50 6 4.24§ 52.97 6 7.69§
Preserved PGA 60.50 6 6.77jj 107.54 6 12.19**
PF PGA 23.00 6 12.60†† 71.97 6 14.88‡‡
DC, dendritic cells; DCD, dendritic cell density; DCL, dendritic cell
length; DED, dry eye disease; PF, preservative-free.
* P < 0.001 versus DED.
† P < 0.05 versus controls; P < 0.001 versus DED.
‡ P¼ 0.002 versus controls; P < 0.001 versus DED.
§ P < 0.001 versus DED.
jj P¼0.03 versus PF b-blockers; P < 0.05 versus PF PGA; P < 0.001
versus controls and dry eye.
** P < 0.001 versus PF b-blockers; P < 0.05 versus PF PGA; P <
0.001 versus controls and DED.
†† P < 0.001 versus DED.
‡‡ P < 0.05 versus controls; P < 0.001 versus DED.
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glaucoma-related OSD has not been adequately investigated.
For the most part, studies have focused on alterations of
epithelial cells, subbasal nerve plexus, stromal keratocytes, and
endothelium, while also reporting limited information regard-
ing DCs,1,3–5 despite the DC density correlates with corneal
inflammation; and the corneal inflammatory status plays a
primary role in glaucoma-related OSD.11,23,24 In histology, DCs
were observed within the limbus and conjunctiva of patients
with glaucoma, expressing proinflammatory cytokines and
showing the mature phenotype.2,25 Using confocal microscopy
of DCs was described within the epithelium and the basement
membrane of the conjunctiva and within the limbal and central
epithelia of the cornea.3,4,8,26,27
In our study, DCs were much more common in MCGP than
in healthy eyes and, in line with the DCs distribution in normal
and under inflammatory conditions, they were represented
more highly at the limbus than at the central cor-
nea.11,12,15,20,28
Interestingly, in glaucomatous patients receiving multitreat-
ment therapy and in patients with dry eye, DCs were observed
in a similar percentage of individuals, suggesting that glaucoma
medications and dry eye may have a similar impact in terms of
corneal inflammation occurrence.
Overall, in patients with glaucoma, the DC density was 2 to
3 times higher at the limbus, and more than 10 times higher in
the central cornea than that in healthy controls. In more detail,
a 2- to 3-fold higher limbal and central DC density were found
in the multitherapy regimen than in the monotherapy regimen,
with several cells presenting the mature phenotype.
Patients with DED showed higher DC density than the
glaucomatous patients receiving multitherapy, with almost
similar morphologic features of DCs. Despite the significant
differences between these groups, probably due to the greater
inflammation induced by autoimmune disorders (such as
Sjögren syndrome), the high DC density values also in group
2 suggest the presence of a similar immunoinflammatory
microenvironment in DED and glaucoma therapy-related OSD.
Other studies confirm this hypothesis, because in patients with
Sjögren syndrome, DC densities were similar to those observed
in glaucoma treated with multitherapy in our study (127.9 6
23.7 cells/mm2 and 157.2 6 29.7 cells/mm2 in the central and
peripheral cornea, respectively).20 These findings appear to be
confirmed further by the fact that, in our study, the corneal
staining was markedly increased in both group 2 and DED,
with values not significantly different. Although with mild
differences, these results were also in line with those reported
in the corneoscleral limbus, in which DC density, OSDI, and
corneal staining were found similarly increased in multitreated
glaucoma and dry eye.8
However, given the retrospective nature of the study,
whether the DC density increase depends on the primary
toxicity of medications1,3–5,8 or is a consequence of the
iatrogenic dry eye cannot be determined.
Conversely, our findings appear in contrast with the results
of a recent study of Villani et al.,26 who reported that, in stable
medically controlled primary open-angle glaucoma, the ocular
surface changes due to the therapy are mostly subclinical.26
This could depend on different variables, such as the duration
of the disease and therapy (which were not reported in that
study), the concomitant (or past) use of lubricants and/or anti-
inflammatory agents to contain the OSD, or an inter-individual
variability in the response to the drug-mediated toxicity and
inflammation.
When we focused on monotherapies, we observed pre-
served medications induced higher DC density than the
corresponding PF formulations, due to the ability of BAK to
increase inflammatory mediators and, thus, to promote
maturation and recruitment of DCs.8,15,26
Zhivov et al.21 confirmed this hypothesis as reported that
after 12 weeks of administration of BAK 0.01% eye drops in
healthy volunteers, the Langerhans cells density significantly
increased in the central and limbal corneal epithelia. Similar
findings were observed in patients with glaucoma, where high
levels of activated Langerhans cells were found in 100% of eyes
after 12 months of therapy with preserved medications
(Zhivov A, et al. IOVS 2007;48:ARVO E-Abstract 4303). The
deep stimulating effect of BAK on DCs was further supported
by a recent confocal study in which BAK-preserved travoprost
induced a higher corneal DC density than polyquad-preserved
travoprost.29
Because we did not find significant differences between
preserved PGA and preserved b-blockers or between PF PGA
and PF b-blockers, we cannot determine whether the
preservative or the active compound played the main role in
the final DC increase. However, because preserved PGA
produced the highest degree of DCs stimulation, one may
hypothesize that, even though both preservative and active
compound are required to recruit DCs, PGA appear more
triggering that b-blockers. This is in agreement with previous
studies, which documented the high inflammatory effect of
this class of medication also on other ocular surface
structures.3,6,8
One of the most remarkable considerations is that DC
density steeply increases when patients move from a mono- to
a multitherapy. Thus, besides the duration of therapy, the
number of daily instillations and the cumulative exposure to
BAK appear as the most important factors leading to the burst
of the corneal inflammation.
Comparing our results with those reported in different
immune-mediated inflammatory corneal diseases, the data
were conflicting. On one hand, in patients with keratitis or
graft rejection after keratoplasty, Mayer et al.28 found central
DC density values very similar to those we found in multi-
treated glaucoma patients. On the other hand, in analogous
conditions, Mastropasqua et al.11 reported DC density mark-
edly higher.
These differences could depend on the high interindividual
variability of DCs, the different immunogenicity of antigens,
the nature of the immune disorders, and the stage of the
disease, which may affect the intensity of the corneal response
to the inflammatory triggers. Nevertheless, despite certain
differences, our results may imply that the corneal microen-
vironment in glaucoma could be similar to an immune-
mediated condition, even though with a less intense inflam-
matory component.
Some limitations need to be pointed out. First, this is a
retrospective study; thus, we cannot establish whether DCs
increase first at the limbus or at the central cornea, although
Zhivov et al.21 reported that Langerhans cells increase more
rapidly in the center than in the periphery after BAK exposure.
It may be hypothesized that the iatrogenic stimulation first
leads DCs to migrate from the limbus (where more of these
cells are found) toward the central cornea, with a concomitant
or subsequent activation of resident central stroma DCs. To
clarify this point, prospective studies in patients näıve to
therapy are required. Second, IVCM provides only morpholog-
ic and morphometric data for DCs; therefore, other cell
phenotypes may be included in error in this cell population.
Third, we did not investigate other corneal features, that is, we
cannot state whether the DC density correlates with other
crucial corneal changes such as those affecting the subbasal
nerve plexus or the superficial epithelial layers.
In conclusion, IOP-lowering medications deeply trigger
corneal DCs, which convert to their mature form and populate
the entire cornea widely. The presence of BAK and the number
of medications daily used represent the most important
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contributing factors for the DCs increase. Moreover, the strong
correlation between DC density and OSDI score supports the
hypothesis of a role for DCs in glaucoma-related OSD, giving a
clinical weight to these findings. This is in agreement with the
recent interpretation of the glaucoma-related OSD as a neuro-
inflammatory process, in which corneal nerves alterations and
the DCs increase were the most important modifications.26
Further dedicated studies are needed to define the exact role of
corneal DCs in the development and maintenance of glaucoma-
related OSD.
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